Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 213

    1.

    Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.

    Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ.

    Breast Cancer Res. 2007;9(5):R65.

    PMID:
    17910759
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.

    Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T.

    Breast Cancer. 2010 Apr;17(2):118-24. Epub 2009 May 23.

    PMID:
    19466512
    [PubMed - indexed for MEDLINE]
    3.

    Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.

    Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Fernö M, Isola J.

    Breast Cancer Res. 2007;9(1):R16.

    PMID:
    17263897
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    4.

    Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.

    Bryan BB, Schnitt SJ, Collins LC.

    Mod Pathol. 2006 May;19(5):617-21.

    PMID:
    16528377
    [PubMed - indexed for MEDLINE]
    Free Article
    5.

    Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.

    Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE.

    Am J Surg Pathol. 2009 Jul;33(7):1093-7.

    PMID:
    19390427
    [PubMed - indexed for MEDLINE]
    6.

    RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.

    Habashy HO, Powe DG, Glaab E, Ball G, Spiteri I, Krasnogor N, Garibaldi JM, Rakha EA, Green AR, Caldas C, Ellis IO.

    Breast Cancer Res Treat. 2011 Jul;128(2):315-26. Epub 2010 Aug 10.

    PMID:
    20697807
    [PubMed - indexed for MEDLINE]
    7.

    Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.

    Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H, Tang P.

    Hum Pathol. 2008 Dec;39(12):1809-15. Epub 2008 Aug 19.

    PMID:
    18715613
    [PubMed - indexed for MEDLINE]
    8.

    Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

    Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

    Clin Cancer Res. 2008 Mar 1;14(5):1368-76.

    PMID:
    18316557
    [PubMed - indexed for MEDLINE]
    Free Article
    9.

    Triple negative breast cancers: clinical and prognostic implications.

    Dawson SJ, Provenzano E, Caldas C.

    Eur J Cancer. 2009 Sep;45 Suppl 1:27-40. Review.

    PMID:
    19775602
    [PubMed - indexed for MEDLINE]
    10.

    Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.

    Diaz LK, Cryns VL, Symmans WF, Sneige N.

    Adv Anat Pathol. 2007 Nov;14(6):419-30. Review.

    PMID:
    18049131
    [PubMed - indexed for MEDLINE]
    11.

    Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

    Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM.

    Clin Cancer Res. 2004 Aug 15;10(16):5367-74.

    PMID:
    15328174
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.

    Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM.

    Histopathology. 2009 Sep;55(3):346-52.

    PMID:
    19723150
    [PubMed - indexed for MEDLINE]
    13.

    Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.

    Rennstam K, McMichael N, Berglund P, Honeth G, Hegardt C, Rydén L, Luts L, Bendahl PO, Hedenfalk I.

    Breast Cancer Res Treat. 2010 Jul;122(2):315-24. Epub 2009 Oct 1.

    PMID:
    19795205
    [PubMed - indexed for MEDLINE]
    14.

    How basal are triple-negative breast cancers?

    Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, Birnbaum D.

    Int J Cancer. 2008 Jul 1;123(1):236-40.

    PMID:
    18398844
    [PubMed - indexed for MEDLINE]
    15.

    IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.

    Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A.

    Hum Pathol. 2009 Nov;40(11):1528-33. Epub 2009 Aug 19.

    PMID:
    19695680
    [PubMed - indexed for MEDLINE]
    16.

    Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.

    Mook S, Knauer M, Bueno-de-Mesquita JM, Retel VP, Wesseling J, Linn SC, Van't Veer LJ, Rutgers EJ.

    Ann Surg Oncol. 2010 May;17(5):1406-13. Epub 2010 Jan 22.

    PMID:
    20094918
    [PubMed - indexed for MEDLINE]
    17.

    Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.

    Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.

    Hum Pathol. 2008 Feb;39(2):167-74. Epub 2007 Nov 28.

    PMID:
    18045647
    [PubMed - indexed for MEDLINE]
    18.

    Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.

    Pintens S, Neven P, Drijkoningen M, Van Belle V, Moerman P, Christiaens MR, Smeets A, Wildiers H, Vanden Bempt I.

    J Clin Pathol. 2009 Jul;62(7):624-8.

    PMID:
    19561231
    [PubMed - indexed for MEDLINE]
    19.

    Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features.

    Ishihara A, Tsuda H, Kitagawa K, Yoneda M, Shiraishi T.

    Breast Cancer. 2009;16(3):179-85. Epub 2009 May 23.

    PMID:
    19466513
    [PubMed - indexed for MEDLINE]
    20.

    Triple negative tumours: a critical review.

    Reis-Filho JS, Tutt AN.

    Histopathology. 2008 Jan;52(1):108-18. Review.

    PMID:
    18171422
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk